利奥西呱：可溶性鸟苷酸环化酶刺激剂。治疗肺动脉高压和无法手术的慢性血栓栓塞性肺动脉高压的新作用模式
[Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].
作者信息
Leuchte H H, Behr J, Ewert R, Ghofrani H A, Grünig E, Halank M, Held M, Klose H, Rosenkranz S, Schermuly R T, Wilkens H, Hoeper M M
机构信息
Innere Medizin II, KH Neuwittelsbach, Akademisches Lehrkrankenhaus LMU, München.
Medizinische Klinik und Polklinik V, Klinikum der Universität München und Asklepios Fachkliniken München-Gauting, Comprehensive Pneumology Center, Mitglied des Deutschen Zentrums für Lungenforschung.
出版信息
Pneumologie. 2015 Mar;69(3):135-43. doi: 10.1055/s-0034-1391435. Epub 2015 Mar 6.
Riociguat is the first clinically available soluble Guanylate-cyclase stimulator (sGC) and representative of a completely new class of drugs. Riociguat is approved for pulmonary arterial hypertension (PAH) and non-operable or recurrent/persistent chronic thromboembolic pulmonary hypertension (CTEPH). Moreover, Riociguat is currently under investigation for a wider spectrum of diseases. This article focusses on its mode of action and clinical trial data. Finally, based on these data, the status of approval, as well as the costs a proposal is given how Riociguat can be integrated in the current treatment of PAH and CTEPH.
利奥西呱是首个临床可用的可溶性鸟苷酸环化酶刺激剂（sGC），代表了一类全新的药物。利奥西呱已被批准用于治疗肺动脉高压（PAH）以及无法手术或复发/持续性慢性血栓栓塞性肺动脉高压（CTEPH）。此外，利奥西呱目前正在针对更广泛的疾病谱进行研究。本文重点关注其作用机制和临床试验数据。最后，基于这些数据，给出了利奥西呱的获批情况、成本，以及关于如何将其纳入PAH和CTEPH当前治疗方案的建议。
Zotero 插件